Loading
Comparing two doses of trastuzumab deruxtecan in HER2-mutant lung cancer showed that the lower 5.4 mg/kg dose gave the same response rate of about half with far less lung toxicity, fixing the approved dose.
Randomised phase 2 trial of 152 patients with previously treated HER2-mutant metastatic non-small-cell lung cancer randomised 2:1 to trastuzumab deruxtecan 5.4 or 6.4 mg/kg.
Objective response was 49.0 percent at 5.4 mg/kg and 56.0 percent at 6.4 mg/kg, with median durations of 16.8 and 5.9 months; adjudicated interstitial lung disease was 12.9 versus 28.0 percent.
Trastuzumab deruxtecan 5.4 mg/kg is the approved regimen for HER2-mutant lung cancer after platinum chemotherapy, and the trial is a rare example of dose optimisation improving safety without losing efficacy.
Shares HER2-mutant non-small-cell lung cancer, Trastuzumab deruxtecan, Trastuzumab.
Shares HER2-mutant non-small-cell lung cancer, Trastuzumab deruxtecan.
Shares Trastuzumab deruxtecan, Trastuzumab, Journal of Clinical Oncology.
Shares Trastuzumab, Journal of Clinical Oncology.
Shares HER2-mutant non-small-cell lung cancer, Trastuzumab deruxtecan.
Shares HER2-mutant non-small-cell lung cancer, Trastuzumab deruxtecan.
Shares HER2-mutant non-small-cell lung cancer, Trastuzumab deruxtecan.
Shares Trastuzumab, Journal of Clinical Oncology.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/